News

A recent study found that some PBC patients face more barriers to care, leading to a delay in diagnosis and treatment.

A recent study showed irritable bowel syndrome (IBD) is a risk factor for primary biliary cholangitis (PBC).

A phase 2b clinical trial has shown positive preliminary results for volixibat intended for the treatment of PBC.

Ipsen’s Iqirvo (elafibranor) is the first new medicine approved in nearly a decade for the treatment of the PBC, according to a recent press release.

A recent study showed that among patients with PBC cirrhosis, decreased diversity and richness of the gut microbiota were observed.

A recent study showed patients with PBC and AIH have immunologic profiles that share both similarities and differences.

Ipsen is recruiting participants for a trial assessing the safety and efficacy of elafibranor in primary biliary cholangitis (PBC).

A recent study showed the PTPN2 gene may be associated with increased risk for primary biliary cholangitis (PBC).

According to interim phase 2 data, golexanolone has a favorable safety and tolerability profile in people with PBC.

A recent study shows prompt identification of extrahepatic conditions (EHCs) is of key importance for the precise, timely diagnosis of PBC.